@article{Birkinshaw2017,
abstract = {Apoptosis is a form of programmed cell death critical for the development and homeostasis of multicellular organisms. A key event within the mitochondrial pathway to apoptosis is the permeabilisation of the mitochondrial outer membrane (MOM), a point of no return in apoptotic progression. This event is governed by a complex interplay of interactions between BCL-2 family members. Here we discuss the roles of opposing factions within the family. We focus on the structural details of these interactions, how they promote or prevent apoptosis and recent developments towards understanding the conformational changes of BAK and BAX that lead to MOM permeabilisation. These interactions and structural insights are of particular interest for drug discovery, as highlighted by the development of therapeutics that target pro-survival family members and restore apoptosis in cancer cells.},
author = {Birkinshaw, Richard W. and Czabotar, Peter E.},
doi = {10.1016/j.semcdb.2017.04.001},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Czabotar{\_}Bcl2{\_}review{\_}17.pdf:pdf},
issn = {10963634},
journal = {Semin. Cell Dev. Biol.},
keywords = {Apoptosis,BAK,BAX,BCL-2 family proteins,Mitochondrial outer membrane permeabilisation,Oligomers},
pages = {152--162},
publisher = {Elsevier Ltd},
title = {{The BCL-2 family of proteins and mitochondrial outer membrane permeabilisation}},
url = {https://doi.org/10.1016/j.semcdb.2017.04.001},
volume = {72},
year = {2017}
}

@article{Niu2017,
author = {Niu, Xin and Brahmbhatt, Hetal and Mergenthaler, Philipp and Zhang, Zhi and Sang, Jing and Daude, Michael and Ehlert, Fabian G. R. and Diederich, Wibke E. and Wong, Eve and Zhu, Weijia and Pogmore, Justin and Nandy, Jyoti P. and Satyanarayana, Maragani and Jimmidi, Ravi K. and Arya, Prabhat and Leber, Brian and Lin, Jialing and Culmsee, Carsten and Yi, Jing and Andrews, David W},
doi = {10.1016/j.chembiol.2017.03.011},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Andrews{\_}BAX{\_}BAK{\_}inhibitors{\_}17.pdf:pdf},
issn = {2451-9456},
journal = {Cell Chem. Biol.},
pages = {493--506},
title = {{A small-molecule inhibitor of Bax and Bak oligomerization prevents genotoxic cell death and promotes neuroprotection}},
url = {http://dx.doi.org/10.1016/j.chembiol.2017.03.011},
volume = {24},
year = {2017}
}

@article{Lovell2008,
abstract = {In normal circumstances, the Bcl-2 family dutifully governs when cells die. However, the rules of engagement between the pro- and antiapoptotic family members are still contested, and how Bax is transformed from a cytosolic monomer to an outer mitochondrial membrane-permeabilizing oligomer is unclear. With fluorescence techniques and an in vitro system, the combination of tBid and Bax produced dramatic membrane permeabilization. The membrane is not a passive partner in this process beause membranes are required for the protein-protein interactions to occur. Simultaneous measurements of these interactions revealed an ordered series of steps required for outer membrane permeabilization: (1) tBid rapidly binds to membranes, where (2) tBid interacts with Bax, causing (3) Bax insertion into membranes and (4) oligomerization, culminating in (5) membrane permeabilization. Bcl-XL prevents membrane-bound tBid from binding Bax. Bad releases tBid from Bcl-XL, restoring both tBid binding to Bax and membrane permeabilization. {\textcopyright} 2008 Elsevier Inc. All rights reserved.},
author = {Lovell, Jonathan F. and Billen, Lieven P. and Bindner, Scott and Shamas-Din, Aisha and Fradin, Cecile and Leber, Brian and Andrews, David W.},
doi = {10.1016/j.cell.2008.11.010},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Andrews{\_}Bax{\_}MOMP{\_}08.pdf:pdf},
isbn = {1097-4172 (Electronic)$\backslash$n0092-8674 (Linking)},
issn = {00928674},
journal = {Cell},
keywords = {CELLBIO,SIGNALING},
pages = {1074--1084},
pmid = {19062087},
publisher = {Elsevier Ltd},
title = {{Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax}},
url = {http://dx.doi.org/10.1016/j.cell.2008.11.010},
volume = {135},
year = {2008}
}

@article{Andrews2014,
abstract = {In this issue, Bleicken et al. (2014) use double electron-electron resonance (DEER) spectroscopy to propose a new model for the active form of Bax at membranes that differs significantly from those previously proposed.},
author = {Andrews, David W.},
doi = {10.1016/j.molcel.2014.11.005},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Andrews{\_}review{\_}14.pdf:pdf},
isbn = {1097-4164 (Electronic) 1097-2765 (Linking)},
issn = {10974164},
journal = {Mol. Cell},
pages = {465--466},
pmid = {25459877},
publisher = {Elsevier Inc.},
title = {{Pores of no return}},
volume = {56},
year = {2014}
}

@article{Luna-Vargas2016,
abstract = {Cellular commitment to the mitochondrial pathway of apoptosis is accomplished when proapoptotic B cell chronic lymphocytic leukemia/lymphoma (BCL)-2 proteins compromise mitochondrial integrity through the process of mitochondrial outer membrane permeabilization (MOMP). For nearly three decades, intensive efforts focused on the identification and interactions of two key proapoptotic BCL-2 proteins: BCL-2 antagonist killer (BAK) and BCL-2-associated X (BAX). Indeed, we now have critical insights into which BCL-2 proteins interact with BAK/BAX to either preserve survival or initiate MOMP. In contrast, while mitochondria are targeted by BAK/BAX, a molecular understanding of how these organelles govern BAK/BAX function remains less clear. Here, we integrate recent mechanistic insights of proapoptotic BCL-2 protein function in the context of mitochondrial environment, and discuss current and potential pharmacological opportunities to control MOMP in disease.},
author = {Luna-Vargas, Mark P.A. and Chipuk, Jerry Edward},
doi = {10.1016/j.tcb.2016.07.002},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Chipuk{\_}Bak{\_}Bax{\_}review{\_}16.pdf:pdf},
issn = {18793088},
journal = {Trends Cell Biol.},
keywords = {BCL-2 family,BH3 mimetics,apoptosis,mitochondria,mitochondrial outer membrane permeabilization},
number = {12},
pages = {906--917},
pmid = {27498846},
publisher = {Elsevier Ltd},
title = {{Physiological and pharmacological control of BAK, BAX, and beyond}},
volume = {26},
year = {2016}
}

@article{Czabotar2013,
abstract = {In stressed cells, apoptosis ensues when Bcl-2 family members Bax or Bak oligomerize and permeabilize the mitochondrial outer membrane. Certain BH3-only relatives can directly activate them to mediate this pivotal, poorly understood step. To clarify the conformational changes that induce Bax oligomerization, we determined crystal structures of Bax$\Delta$C21 treated with detergents and BH3 peptides. The peptides bound the Bax canonical surface groove but, unlike their complexes with prosurvival relatives, dissociated Bax into two domains. The structures define the sequence signature of activator BH3 domains and reveal how they can activate Bax via its groove by favoring release of its BH3 domain. Furthermore, Bax helices $\alpha$2-$\alpha$5 alone adopted a symmetric homodimer structure, supporting the proposal that two Bax molecules insert their BH3 domain into each other's surface groove to nucleate oligomerization. A planar lipophilic surface on this homodimer may engage the membrane. Our results thus define critical Bax transitions toward apoptosis. {\textcopyright} 2013 Elsevier Inc.},
author = {Czabotar, Peter E. and Westphal, Dana and Dewson, Grant and Ma, Stephen and Hockings, Colin and Fairlie, W. Douglas and Lee, Erinna F. and Yao, Shenggen and Robin, Adeline Y. and Smith, Brian J. and Huang, David C.S. and Kluck, Ruth M. and Adams, Jerry M. and Colman, Peter M.},
doi = {10.1016/j.cell.2012.12.031},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Colman{\_}bax{\_}crystal{\_}13.pdf:pdf},
isbn = {0092-8674},
issn = {00928674},
journal = {Cell},
number = {3},
pages = {519--531},
pmid = {23374347},
publisher = {Elsevier Inc.},
title = {{Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis}},
url = {http://dx.doi.org/10.1016/j.cell.2012.12.031},
volume = {152},
year = {2013}
}

@article{Souers2013,
abstract = {Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells evade apoptosis. The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers. However, concomitant on-target thrombocytopenia caused by BCL-X(L) inhibition limits the efficacy achievable with this agent. Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2-selective inhibitor, ABT-199. This compound inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2-dependent hematological cancers.},
author = {Souers, Andrew J. and Leverson, Joel D. and Boghaert, Erwin R. and Ackler, Scott L. and Catron, Nathaniel D. and Chen, Jun and Dayton, Brian D. and Ding, Hong and Enschede, Sari H. and Fairbrother, Wayne J. and Huang, David C.S. and Hymowitz, Sarah G. and Jin, Sha and Khaw, Seong Lin and Kovar, Peter J. and Lam, Lloyd T. and Lee, Jackie and Maecker, Heather L. and Marsh, Kennan C. and Mason, Kylie D. and Mitten, Michael J. and Nimmer, Paul M. and Oleksijew, Anatol and Park, Chang H. and Park, Cheol Min and Phillips, Darren C. and Roberts, Andrew W. and Sampath, Deepak and Seymour, John F. and Smith, Morey L. and Sullivan, Gerard M. and Tahir, Stephen K. and Tse, Chris and Wendt, Michael D. and Xiao, Yu and Xue, John C. and Zhang, Haichao and Humerickhouse, Rod A. and Rosenberg, Saul H. and Elmore, Steven W.},
doi = {10.1038/nm.3048},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Elmore{\_}ABT199{\_}13.pdf:pdf},
isbn = {1546-170X (Electronic)$\backslash$r1078-8956 (Linking)},
issn = {10788956},
journal = {Nat. Med.},
pages = {202--208},
pmid = {23291630},
publisher = {Nature Publishing Group},
title = {{ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets}},
url = {http://dx.doi.org/10.1038/nm.3048},
volume = {19},
year = {2013}
}

@article{Tse2008,
abstract = {Overexpression of the prosurvival Bcl-2 family members (Bcl-2, Bcl-xL, and Mcl-1) is commonly associated with tumor maintenance, progression, and chemoresistance. We previously reported the discovery of ABT-737, a potent, small-molecule Bcl-2 family protein inhibitor. A major limitation of ABT-737 is that it is not orally bioavailable, which would limit chronic single agent therapy and flexibility to dose in combination regimens. Here we report the biological properties of ABT-263, a potent, orally bioavailable Bad-like BH3 mimetic (K(i)'s of {\textless}1 nmol/L for Bcl-2, Bcl-xL, and Bcl-w). The oral bioavailability of ABT-263 in preclinical animal models is 20{\%} to 50{\%}, depending on formulation. ABT-263 disrupts Bcl-2/Bcl-xL interactions with pro-death proteins (e.g., Bim), leading to the initiation of apoptosis within 2 hours posttreatment. In human tumor cells, ABT-263 induces Bax translocation, cytochrome c release, and subsequent apoptosis. Oral administration of ABT-263 alone induces complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 exhibits modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. These data provide the rationale for clinical trials evaluating ABT-263 in small-cell lung cancer and B-cell malignancies. The oral efficacy of ABT-263 should provide dosing flexibility to maximize clinical utility both as a single agent and in combination regimens.},
author = {Tse, Christin and Shoemaker, Alexander R. and Adickes, Jessica and Anderson, Mark G. and Chen, Jun and Jin, Sha and Johnson, Eric F. and Marsh, Kennan C. and Mitten, Michael J. and Nimmer, Paul and Roberts, Lisa and Tahir, Stephen K. and Xiao, Yu and Yang, Xiufen and Zhang, Haichao and Fesik, Stephen and Rosenberg, Saul H. and Elmore, Steven W.},
doi = {10.1158/0008-5472.CAN-07-5836},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Elmore{\_}ABT263{\_}08.pdf:pdf},
isbn = {1538-7445 (Electronic)$\backslash$r0008-5472 (Linking)},
issn = {00085472},
journal = {Cancer Res.},
pages = {3421--3428},
pmid = {18451170},
title = {{ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor}},
volume = {68},
year = {2008}
}

@article{Cosentino2017,
abstract = {Bax and its homolog Bak are key regulators of the mitochondrial pathway of apoptosis. On cell stress Bax and Bak accumulate at distinct foci on the mitochondrial surface where they undergo a conformational change, oligomerize, and mediate cytochrome c release, leading to cell death. The molecular mechanisms of Bax and Bak assembly and mitochondrial permeabilization have remained a longstanding question in the field. Recent structural and biophysical studies at several length scales have shed light on key aspects of Bax and Bak function that have shifted how we think this process occurs. These discoveries reveal an unexpected molecular mechanism in which Bax (and likely Bak) dimers assemble into oligomers with an even number of molecules that fully or partially delineate pores of different sizes to permeabilize the mitochondrial outer membrane (MOM) during apoptosis.},
author = {Cosentino, Katia and Garc{\'{i}}a-S{\'{a}}ez, Ana J.},
doi = {10.1016/j.tcb.2016.11.004},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Garcia-Saez{\_}Bax{\_}Bak{\_}review{\_}17.pdf:pdf},
isbn = {1879-3088 (Electronic) 0962-8924 (Linking)},
issn = {18793088},
journal = {Trends Cell Biol.},
keywords = {Bax,Bcl-2 proteins,apoptosis,cell death,mitochondrial outer membrane permeabilization,pore-forming proteins},
pages = {266--275},
pmid = {27932064},
publisher = {Elsevier Ltd},
title = {{Bax and Bak pores: Are we closing the circle?}},
volume = {27},
year = {2017}
}

@article{Garcia-Saez2012,
abstract = {The Bcl-2 family of proteins is formed by pro- and antiapoptotic members. Together they regulate the permeabilization of the mitochondrial outer membrane, a key step in apoptosis. Their complex network of interactions both in the cytosol and on mitochondria determines the fate of the cell. In the past 2 decades, the members of the family have been identified and classified according to their function. Several competing models have been proposed to explain how the Blc-2 proteins orchestrate apoptosis signaling. However, basic aspects of the action of these proteins remain elusive. This review is focused on the biophysical mechanisms that are relevant for their action in apoptosis and on the challenging gaps in our knowledge that necessitate further exploration to finally understand how the Bcl-2 family regulates apoptosis.},
author = {Garc{\'{i}}a-S{\'{a}}ez, A. J.},
doi = {10.1038/cdd.2012.105},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Garcia-Saez{\_}Bcl2{\_}review{\_}12.pdf:pdf},
isbn = {1476-5403 (Electronic)$\backslash$r1350-9047 (Linking)},
issn = {13509047},
journal = {Cell Death Differ.},
keywords = {apoptosis,interaction network,membrane permeabilization,mitochondrial membrane},
pages = {1733--1740},
pmid = {22935609},
title = {{The secrets of the Bcl-2 family}},
volume = {19},
year = {2012}
}

@article{Moldoveanu2013,
abstract = {The BCL-2-family protein BAK is responsible for mitochondrial outer-membrane permeabilization (MOMP), which leads to apoptosis. The BCL-2 homology 3 (BH3)-only protein BID activates BAK to perform this function. We report the NMR solution structure of the human BID BH3-BAK complex, which identified the activation site at the canonical BH3-binding groove of BAK. Mutating the BAK BH1 in the groove prevented activation and MOMP but not the binding of BID. BAK BH3 mutations allowed BID binding and activation but blunted function by blocking BAK oligomerization. BAK activation follows a 'hit-and-run' mechanism whereby BID dissociates from the trigger site, which allows BAK oligomerization at an overlapping interface. In contrast, the BH3-only proteins NOXA and BAD are predicted to clash with the trigger site and are not activators of BAK. These findings provide insights into the early stages of BAK activation.},
author = {Moldoveanu, Tudor and Grace, Christy R. and Llambi, Fabien and Nourse, Amanda and Fitzgerald, Patrick and Gehring, Kalle and Kriwacki, Richard W. and Green, Douglas R.},
doi = {10.1038/nsmb2563},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Green{\_}BAK{\_}BID{\_}13.pdf:pdf},
isbn = {1545-9985 (Electronic)$\backslash$r1545-9985 (Linking)},
issn = {15459985},
journal = {Nat. Struct. Mol. Biol.},
pages = {589--597},
pmid = {23604079},
publisher = {Nature Publishing Group},
title = {{BID-induced structural changes in BAK promote apoptosis}},
url = {http://dx.doi.org/10.1038/nsmb.2563},
volume = {20},
year = {2013}
}

@article{Bombrun2003,
abstract = {There is compelling evidence that Bax channel activity stimulates cytochrome c release leading ultimately to cell death, which is a key event in ischemic injuries and neurodegenerative diseases. Here 3,6-dibromocarbazole piperazine derivatives of 2-propanol are described as the first small and potent modulators of the cytochrome c release triggered by Bid-induced Bax activation in a mitochondrial assay. Furthermore, a mechanism of action is proposed, and fluorescent derivatives allowing the localization of such inhibitors are reported.},
author = {Bombrun, Agnes and Gerber, Patrick and Casi, Giulio and Terradillos, Olivier and Antonsson, Bruno and Halazy, Serge},
doi = {10.1021/jm034107j},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Halazy{\_}Bax{\_}channel{\_}inhibitor{\_}03.pdf:pdf},
isbn = {0022-2623 (Print)$\backslash$n0022-2623 (Linking)},
issn = {00222623},
journal = {J. Med. Chem.},
pages = {4365--4368},
pmid = {14521400},
title = {{3,6-Dibromocarbazole piperazine derivatives of 2-propanol as first inhibitors of cytochrome C release via bax channel modulation}},
volume = {46},
year = {2003}
}

@article{Peixoto2009,
abstract = {MAC (mitochondrial apoptosis-induced channel) forms in the mitochondrial outer membrane and unleashes cytochrome c to orchestrate the execution of the cell. MAC opening is the commitment step of intrinsic apoptosis. Hence closure of MAC may prevent apoptosis. Compounds that blocked the release of fluorescein from liposomes by recombinant Bax were tested for their ability to directly close MAC and suppress apoptosis in FL5.12 cells. Low doses of these compounds (IC50 values ranged from 19 to 966 nM) irreversibly closed MAC. These compounds also blocked cytochrome c release and halted the onset of apoptotic markers normally induced by IL-3 (interleukin-3) deprivation or staurosporine. Our results reveal the tight link among MAC activity, cytochrome c release and apoptotic death, and indicate this mitochondrial channel is a promising therapeutic target.},
author = {Peixoto, Pablo M and Ryu, Shin-young and Bombrun, Agnes and Antonsson, Bruno and Kinnally, Kathleen W},
doi = {10.1042/BJ20090664},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Kinnally{\_}iMac2{\_}09.pdf:pdf},
isbn = {1470-8728 (Electronic)$\backslash$r0264-6021 (Linking)},
issn = {1470-8728},
journal = {Biochem. J.},
keywords = {Animals,Apoptosis,Apoptosis: drug effects,Cell Line,Cytochromes c,Cytochromes c: metabolism,Enzyme Inhibitors,Enzyme Inhibitors: metabolism,Interleukin-3,Interleukin-3: metabolism,Ion Channels,Ion Channels: antagonists {\{}{\&}{\}} inhibitors,Ion Channels: metabolism,Membrane Transport Modulators,Membrane Transport Modulators: pharmacology,Mice,Mitochondria,Mitochondria: metabolism,Mitochondrial Membranes,Mitochondrial Membranes: metabolism,Recombinant Proteins,Recombinant Proteins: pharmacology,Staurosporine,Staurosporine: pharmacology,bcl-2-Associated X Protein,bcl-2-Associated X Protein: pharmacology},
pages = {381--387},
pmid = {19691447},
title = {{MAC inhibitors suppress mitochondrial apoptosis.}},
url = {http://www.ncbi.nlm.nih.gov/pubmed/19691447},
volume = {423},
year = {2009}
}

@article{Peixoto2017,
abstract = {Mitochondrial Apoptotic Channel inhibitors or iMACs are di-bromocarbazole derivatives with anti-apoptotic function which have been tested and validated in several mouse models of brain injury and neurodegeneration. Owing to the increased therapeutic potential of these com-pounds, we sought to expand our knowledge of their mecha-nism of action. We investigated the kinetics of MAC inhibi-tion in mitochondria from wild type, Bak, and Bax knockout cell lines using patch clamp electrophysiology, fluorescence microscopy, ELISA, and semiquantitative western blot analy-ses. Our results show that iMACs work through at least two mechanisms: 1) by blocking relocation of the cytoplasmic Bax protein to mitochondria and 2) by disassembling Bax and Bak oligomers in the mitochondrial outer membrane. iMACs exert comparable effects on channel conductance of Bax or Bak and similarly affect cytochrome c release from Bax or Bak-containing mitochondria. Interestingly, wild type mitochon-dria were more susceptible to inhibition than the Bak or Bax knockouts. Western blot analysis showed that wild type mitochondria had lower steady state levels of Bak in the ab-sence of apoptotic stimulation.},
author = {Peixoto, Pablo M. and Teijido, Oscar and Mirzalieva, Oygul and Dejean, Laurent M. and Pavlov, Evgeny V. and Antonsson, Bruno and Kinnally, Kathleen W.},
doi = {10.1007/s10863-015-9635-7},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Kinnally{\_}MAC{\_}inhibitor{\_}17.pdf:pdf},
issn = {15736881},
journal = {J. Bioenerg. Biomembr.},
keywords = {Apoptosis,Bak,Bax,MAC inhibitors,MOMP,Patch clamp,tBid},
pages = {65--74},
pmid = {26698318},
publisher = {Journal of Bioenergetics and Biomembranes},
title = {{MAC inhibitors antagonize the pro-apoptotic effects of tBid and disassemble Bax/Bak oligomers}},
volume = {49},
year = {2017}
}

@article{Uren2017,
abstract = {During apoptosis, Bak and Bax undergo major conformational change and form symmetric dimers that coalesce to perforate the mitochondrial outer membrane via an unknown mechanism. We have employed cysteine labelling and linkage analysis to the full length of Bak in mitochondria. This comprehensive survey showed that in each Bak dimer the N-termini are fully solvent-exposed and mobile, the core is highly structured, and the C-termini are flexible but restrained by their contact with the membrane. Dimer-dimer interactions were more labile than the BH3:groove interaction within dimers, suggesting there is no extensive protein interface between dimers. In addition, linkage in the mobile Bak N-terminus (V61C) specifically quantified association between dimers, allowing mathematical simulations of dimer arrangement. Together, our data show that Bak dimers form disordered clusters to generate lipidic pores. These findings provide a molecular explanation for the observed structural heterogeneity of the apoptotic pore.},
author = {Uren, Rachel T. and O'Hely, Martin and Iyer, Sweta and Bartolo, Ray and Shi, Melissa X. and Brouwer, Jason M. and Alsop, Amber E. and Dewson, Grant and Kluck, Ruth M.},
doi = {10.7554/eLife.19944},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Kluck{\_}Bak{\_}dimer{\_}momp{\_}17.pdf:pdf},
isbn = {2050-084X (Electronic) 2050-084X (Linking)},
issn = {2050084X},
journal = {{eLife}},
pages = {1--23},
pmid = {28182867},
title = {{Disordered clusters of bak dimers rupture mitochondria during apoptosis}},
volume = {6},
year = {2017}
}

@article{Westphal2014,
abstract = {The pivotal step on the mitochondrial pathway to apoptosis is permeabilization of the mitochondrial outer membrane (MOM) by oligomers of the B-cell lymphoma-2 (Bcl-2) family members Bak or Bax. However, how they disrupt MOM integrity is unknown. A longstanding model is that activated Bak and Bax insert two $\alpha$-he- lices, $\alpha$5 and $\alpha$6, as a hairpin across the MOM, but recent insights on the oligomer structures question this model. We have clarified how these helices contribute to MOM perforation by determining that, in the oligomers, Bak $\alpha$5 (like Bax $\alpha$5) remains part of the protein core and that a membrane-impermeable cysteine reagent can label cysteines placed at many positions in $\alpha$5 and $\alpha$6 of both Bak and Bax. The results are inconsistent with the hairpin insertion model but support an in-plane model in which $\alpha$5 and $\alpha$6 collapse onto the membrane and insert shallowly to drive formation of proteolipidic pores.},
author = {Westphal, Dana and Dewson, Grant and Menard, Marie and Frederick, Paul and Iyer, Sweta and Bartolo, Ray and Gibson, Leonie and Czabotar, Peter E. and Smith, Brian J. and Adams, Jerry M. and Kluck, Ruth M.},
doi = {10.1073/pnas.1415142111},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Kluck{\_}Bax{\_}Bak{\_}14.pdf:pdf},
isbn = {0027-8424},
issn = {0027-8424},
journal = {Proc. Natl. Acad. Sci.},
number = {39},
pages = {E4076--E4085},
pmid = {25228770},
title = {{Apoptotic pore formation is associated with in-plane insertion of Bak or Bax central helices into the mitochondrial outer membrane}},
url = {http://www.pnas.org/lookup/doi/10.1073/pnas.1415142111},
volume = {111},
year = {2014}
}

@article{Ashkenazi2017,
abstract = {Members of the B cell lymphoma 2 (BCL-2) gene family have a central role in regulating programmed cell death by controlling pro-apoptotic and anti-apoptotic intracellular signals. In cancer, apoptosis evasion through dysregulation of specific BCL-2 family genes is a recurring event; accordingly, selective inhibition of specific anti-apoptotic BCL-2 family proteins represents an exciting therapeutic opportunity. A combination of nuclear magnetic resonance (NMR)-based screening and structure-based drug design has yielded the first bona fide BCL-2 homology 3 (BH3) mimetics, including the BCL-2 and BCL-XL dual antagonist navitoclax, which is the first BCL-2 family inhibitor to show efficacy in patients with cancer. Clinical experience with navitoclax prompted the generation of the highly selective BCL-2 inhibitor venetoclax, which is now approved in the United States for the treatment of patients with chronic lymphocytic leukaemia with 17p deletion who have received at least one prior therapy. Recent advances have also been made in the development of potent and selective inhibitors of BCL-XL and myeloid cell leukaemia 1 (MCL1), which are additional BCL-2 family members with established anti-apoptotic roles in cancer. Here we review the latest progress in direct and selective targeting of BCL-2 family proteins for cancer therapy.},
author = {Ashkenazi, Avi and Fairbrother, Wayne J. and Leverson, Joel D. and Souers, Andrew J.},
doi = {10.1038/nrd.2016.253},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Souers{\_}BCL2{\_}inhibitor{\_}17.pdf:pdf},
issn = {14741784},
journal = {Nat. Rev. Drug Discov.},
number = {4},
pages = {273--284},
pmid = {28209992},
publisher = {Nature Publishing Group},
title = {{From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors}},
volume = {16},
year = {2017}
}

@article{Peng2006,
abstract = {During initiation of apoptosis, Bcl-2 family proteins regulate the permeability of mitochondrial outer membrane. BH3-only protein, tBid, activates pro-apoptotic Bax to release cytochrome c from mitochondria. tBid also activates anti-apoptotic Bcl-2 in the mitochondrial outer membrane, changing it from a single-spanning to a multispanning conformation that binds the active Bax and inhibits cytochrome c release. However, it is not known whether other mitochondrial proteins are required to elicit the tBid-induced Bcl-2 conformational alteration. To define the minimal components that are required for the functionally important Bcl-2 conformational alteration, we reconstituted the reaction using purified proteins and liposomes. We found that purified tBid was sufficient to induce a conformational alteration in the liposome-tethered, but not cytosolic Bcl-2, resulting in a multispanning form that is similar to the one found in the mitochondrial outer membrane of drug-treated cells. Mutations that abolished tBid/Bcl-2 interaction also abolished the conformational alteration, demonstrating that a direct tBid/Bcl-2 interaction at the membrane is both required and sufficient to elicit the conformational alteration. Furthermore, active Bax also elicited the Bcl-2 conformational alteration. Bcl-2 mutants that displayed increased or decreased activity in the conformational alteration assay showed corresponding activities in inhibiting pore formation by Bax in vitro and in preventing apoptosis in vivo. Thus, there is a strong correlation between the direct interaction of membrane-bound Bcl-2 and tBid with activation of Bcl-2 in vitro and in vivo.},
author = {Peng, Jun and Tan, Chibing and Roberts, G. Jane and Nikolaeva, Olga and Zhang, Zhi and Lapolla, Suzanne M. and Primorac, Steve and Andrews, David W. and Lin, Jialing},
doi = {10.1074/jbc.M608303200},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Lin{\_}tBid{\_}Bcl-2{\_}06.pdf:pdf},
isbn = {0021-9258},
issn = {00219258},
journal = {J. Biol. Chem.},
number = {47},
pages = {35802--35811},
pmid = {17005564},
title = {{tBid elicits a conformational alteration in membrane-bound Bcl-2 such that it inhibits Bax pore formation}},
volume = {281},
year = {2006}
}

@article{Zhang2010,
abstract = {Interactions of Bcl-2 family proteins regulate permeability of the mitochondrial outer membrane and apoptosis. In particular, Bax forms an oligomer that permeabilizes the membrane. To map the interface of the Bax oligomer we used Triton X-100 as a membrane surrogate and performed site-specific photocross-linking. Bax-specific adducts were formed through photo-reactive probes at multiple sites that can be grouped into two surfaces. The first surface overlaps with the BH1-3 groove formed by Bcl-2 Homology motif 1, 2, and 3; the second surface is a rear pocket located on the opposite side of the protein from the BH1-3 groove. Further cross-linking experiments using Bax BH3 peptides and mutants demonstrated that the two surfaces interact with their counterparts in neighboring proteins to form two separated interfaces and that interaction at the BH1-3 groove primes the rear pocket for further interaction. Therefore, Bax oligomerization proceeds through a series of interactions that occur at separate, yet allosterically, coupled interfaces.},
author = {Zhang, Zhi and Zhu, Weijia and Lapolla, Suzanne M. and Miao, Yiwei and Shao, Yuanlong and Falcone, Mina and Boreham, Doug and McFarlane, Nicole and Ding, Jingzhen and Johnson, Arthur E. and Zhang, Xuejun C. and Andrews, David W. and Lin, Jialing},
doi = {10.1074/jbc.M110.113456},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Lin{\_}Bax{\_}oligomerization{\_}10.pdf:pdf},
isbn = {1083-351X (Electronic)$\backslash$r0021-9258 (Linking)},
issn = {00219258},
journal = {J. Biol. Chem.},
pages = {17614--17627},
pmid = {20382739},
title = {{Bax forms an oligomer via separate, yet interdependent, surfaces}},
volume = {285},
year = {2010}
}

@article{Zhang2016a,
author = {Zhang, Zhi and Subramaniam, Sabareesh and Kale, Justin and Liao, Chenyi and Huang, Bo and Brahmbhatt, Hetal and Condon, Samson G F and Lapolla, Suzanne M and Hays, Franklin A and Ding, Jingzhen and He, Feng and Xuejun, C and Li, Jianing and Senes, Alessandro and Andrews, David W and Lin, Jialing},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Lin{\_}Bax{\_}dimerization{\_}15.pdf:pdf},
journal = {EMBO J.},
keywords = {apoptosis,bcl- 2 proteins,cell death,drial membranes,intracellular,membrane,membrane permeabilization,mitochon-,oligomerization,structural biology,subject categories autophagy,transport},
pages = {208--236},
title = {{BH3-in-groove dimerization initiates and Helix 9 dimerization expands Bax pore assembly in membranes}},
volume = {35},
year = {2016}
}

@article{Hughes2016,
abstract = {A review. Synthetic routes and final forms for three recently approved oncol. drugs are reviewed: carfilzomib (Kyprolis), osimertinib (Tagrisso), and venetoclax (Venclexta). Several patent applications have been filed for the major synthetic challenge for carfilzomib, installation of the chiral epoxide. The apparent manufg. route to osimertinib involves seven steps and a longest linear sequence of six steps with a yield of 56{\%}. The apparent manufg. route to venetoclax is a ten-step convergent synthesis with a seven-step longest linear sequence that proceeds in 52{\%} yield. [on SciFinder(R)]},
author = {Hughes, David L.},
doi = {10.1021/acs.oprd.6b00374},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Hughes{\_}ABT{\_}synthesis{\_}16.pdf:pdf},
isbn = {1083-6160$\backslash$r1520-586X},
issn = {1520586X},
journal = {Org. Process. Res. Dev.},
pages = {2028--2042},
title = {{Patent review of manufacturing routes to oncology drugs: Carfilzomib, Osimertinib, and Venetoclax}},
volume = {20},
year = {2016}
}

@article{Hunter2018,
abstract = {A convergent approach for the stereoselective synthesis of diverse spiroethers is described. The reaction involves stereoselective trapping of diazo-derived rhodium carbenoids with gold-activated alkynols for the installation of spiro cores. The reaction has proven general with a range of readily accessible homopropargylic alcohols and diazo carbon-yls to provide functionalized spiroether cores of bioactive scaffolds such as spirobarbiturates, spirooxindoles, and pseurotin natural products. â–  INTRODUCTION The spiroether core is found in a wide range of bioactive natural products and drug molecules (Figure 1). 1 Examples include the naturally occurring pseurotins, and spirooxindoles, both natural and synthetic. 2 Griseofulvin, a spiroether drug, is on the World Health Organization list of essential medicines. 3 The importance of this scaffold in drug development can be attributed to the spiro center inducing rigid organization of the overall molecular scaffold, causing the functional groups to be presented to biological targets in well-defined three-dimen-sional orientations to provide increased binding affinity and bioavailability. 4 Due to the biological and therapeutic values, the synthesis of spiroethers remains an area of current interest to the chemical community. 5 The key synthetic challenge is the stereoselective installation of the spiro center. Most methods rely heavily on intramolecular cyclization/rearrangement reactions of an appropriate linear precursor, which requires multiple synthetic steps for preparation (Figure 2a). 6 To overcome this synthetic challenge, we report a convergent approach for the stereoselective synthesis of diverse Figure 1. Examples of spiroether natural products and drug molecules. Figure 2. (a) Approaches for spiroether synthesis. (b) This work. Article pubs.acs.org/joc spiroethers through stereoselective trapping of rhodium carbenoids 7 with gold-activated homopropargylic alcohols (Figure 2b). Notably, this approach enables new Conia-ene cyclizations with diester, ketoamide, diamide, and amide functionalities, which were previously problematic to achieve using gold catalysis as described by the Toste group. 8 This limitation of the gold-catalyzed Conia-ene cyclization was also observed in our previous work related to the synthesis of functionalized tetrahydrofurans and $\gamma$-butyrolactones.},
author = {Hunter, Arianne C and Schlitzer, Steven C and Stevens, Joseph C and Almutwalli, Bilal and Sharma, Indrajeet},
doi = {10.1021/acs.joc.7b03196},
file = {:Users/yihan/Desktop/GitHub/literature/reactions/general{\_}organic{\_}reactions/Sharma{\_}convergent{\_}approach{\_}18.pdf:pdf},
issn = {15206904},
journal = {J. Org. Chem.},
pages = {2744--2752},
title = {{A convergent approach to diverse spiroethers through stereoselective trapping of Rhodium carbenoids with gold-activated alkynols}},
volume = {83},
year = {2018}
}

@article{Tan2006b,
abstract = {Interactions among Bcl-2 family proteins mediated by Bcl-2 homology (BH) regions transform apoptosis signals into actions. The interactions between BH3 region-only proteins and multi-BH region proteins such as Bax and Bcl-2 have been proposed to be the dominant interactions required for initiating apoptosis. Experimental evidence also suggests that both homo- and hetero-interactions are mediated primarily by the BH3 regions in all Bcl-2 family proteins and contribute to commitment to or inhibition of apoptosis. We found that a peptide containing the BH3 helix of Bax was not sufficient to activate recombinant Bax to permeabilize mitochondria. However, an extended peptide containing the BH3 helix and additional downstream sequences activated Bax to permeabilize mitochondria and liposomes. Bcl-2 inhibited the membrane-permeabilizing activity of peptide-activated Bax. This activity of Bcl-2 was inhibited by the extended but not the BH3-only peptide despite both peptides binding to Bcl-2 with similar affinity. Further, membrane-bound Bax activation intermediates directly activated soluble Bax further permeabilizing the membrane. Bcl-2 inhibited Bax auto-activation. We therefore propose that Bax auto-activation amplifies the initial death signal produced by BH3-only proteins and that Bcl-2 functions as an inhibitor of Bax auto-activation.},
author = {Tan, Chibing and Dlugosz, Paulina J. and Peng, Jun and Zhang, Zhi and Lapolla, Suzanne M. and Plafker, Scott M. and Andrews, David W. and Lin, Jialing},
doi = {10.1074/jbc.M602374200},
file = {:Users/yihan/Desktop/GitHub/literature/biology/Bcl-2/Lin{\_}Bcl2{\_}Bax{\_}2006.pdf:pdf},
isbn = {0021-9258},
issn = {00219258},
journal = {J. Biol. Chem.},
pages = {14764--14775},
pmid = {16571718},
title = {{Auto-activation of the apoptosis protein bax increases mitochondrial membrane permeability and is inhibited by Bcl-2}},
volume = {281},
year = {2006}
}

